EBS - Emergent BioSolutions Appoints New President and CEO

2024-02-21 08:04:03 ET

DENVER, Colo., Feb 21, 2024 (www.247marketnews.com)- Emergent BioSolutions Inc. (NYSE: EBS ) reported, this morning, that Joseph C. Papa was appointed president and CEO, effective today.

EBS is trading at $1.71, up $0.19 (+12.50%), on 46K shares traded.

Its 52-week range is $1.42 to $14.39. It hit its 52-low earlier this month and its next key inflection point is $1.84.

“Following a thorough search process, we are pleased to appoint Joe Papa as president and CEO of Emergent,” said Zsolt Harsanyi, Ph.D., chairman of the Board of Directors. “He is a recognized industry leader with unparalleled experience in all facets of the pharmaceutical and healthcare industry. Joe has a solid track record of driving growth and successfully navigating companies through periods of transformation. His leadership will be instrumental in strengthening Emergent’s balance sheet and returning to growth, as we continue to deliver on our mission to protect and enhance life. On behalf of the Board, I would also like to thank Haywood Miller for his leadership and contributions during this interim period.”

“Whether it’s increasing access to NARCAN ^® Nasal Spray, which is helping combat the opioid epidemic, or continuing to deliver important medical countermeasures to customers around the world, Emergent is providing critical products to address global health crises,” said Mr. Papa. “I am confident that these important products provide for a bright future ahead as Emergent continues to lead in public health preparedness. I look forward to working with the team to accelerate the company’s progress, continue improving its financial position and drive value for shareholders. It is a privilege to join Emergent and chart a new chapter in this vital space.”

The post Emergent BioSolutions Appoints New President and CEO first appeared on 24/7 MarketNews .

For further details see: